Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY: DGX )

143.91 +2.95 (+2.09%)
Official Closing Price Updated: 7:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,060,930
Open 141.99
Bid (Size) 142.00 (8)
Ask (Size) 152.70 (1)
Prev. Close 140.96
Today's Range 140.06 - 144.38
52wk Range 119.59 - 150.59
Shares Outstanding 122,180,759
Dividend Yield 1.97%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
5 Analysts Assess Quest Diagnostics: What You Need To Know
Via Benzinga
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says
Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue... 
Via Benzinga

Performance

YTD
+2.19%
+2.19%
1 Month
+2.62%
+2.62%
3 Month
+4.62%
+4.62%
6 Month
+12.64%
+12.64%
1 Year
-0.70%
-0.70%

More News

Read More
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday?
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
Analyst Scoreboard: 7 Ratings For Quest Diagnostics
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Peering Into Quest Diagnostics's Recent Short Interest
Via Benzinga
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Via Benzinga
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Via MarketBeat
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Analyst Landscape: 5 Takes On Quest Diagnostics
Via Benzinga
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
Via AB Newswire
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth
Via Talk Markets
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
Via Benzinga
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
US Stocks Set To Open Fresh Week Higher On Big Tech Earnings Hopes: Analyst Warns Any Letdown Could Push Market 'Deeper Into Oversold Territory'
Via Benzinga
Earnings Scheduled For April 23, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.